Transient ischemic attack (TIA) and acute ischemic or hemorrhagic stroke represent a continuous spectrum of cerebrovascular disease resulting from compromised cerebral blood flow or vascular rupture. A TIA produces transient, focal neurological dysfunction in the absence of acute tissue infarction, whereas acute stroke causes lasting, irreversible neuronal injury. Because TIA serves as a harbinger of imminent stroke and hyperacute stroke interventions are strictly time-dependent, both presentations require rapid emergency evaluation and management.
Clinical Practice Rule
Treat All Sudden Focal Deficits as Medical Emergencies: Sudden focal neurological deficits must be evaluated as hyperacute stroke emergencies regardless of whether symptoms are fluctuating, improving, or completely resolved upon presentation. Tissue resolution on imaging, rather than an arbitrary 24-hour clock, distinguishes modern TIA from ischemic stroke.
1. Pathophysiology & Cerebrovascular Spectrum
Normal neuronal function relies on uninterrupted cerebral arterial perfusion. Interruption of blood flow initiates an ischemic cascade leading to cellular energy failure, membrane depolarization, excitotoxicity, and eventual cell death.
Pathophysiologic Cascade & Tissue Salvage
Arterial Occlusion → Local Perfusion Failure → Ischemic Core Formation (Irreversible Death) → Surrounding Ischemic Penumbra (Hypoperfused, Functionally Silent, Viable Tissue) → Reperfusion Therapy / Tissue Rescue
The biological principle “Time is Brain” underscores that un-perfused penumbral tissue rapidly transitions into irreversible infarction without swift mechanical or pharmacological recanalization.
| Condition | Pathophysiologic Context & Clinical Significance |
|---|---|
| Transient Ischemic Attack (TIA) | Focal brain, spinal cord, or retinal ischemia without acute infarction on tissue imaging (e.g., DWI MRI). Serves as an immediate clinical warning sign of active thromboembolic or vascular pathology (carotid stenosis, atrial fibrillation) carrying high short-term stroke risk. |
| Ischemic Stroke | Persistent cerebral arterial occlusion (thrombus, embolus, or small-vessel lipohyalinosis) resulting in focal neuronal necrosis and structural infarction. Accounts for the majority of cerebrovascular events. |
| Hemorrhagic Stroke & SAH | Nontraumatic parenchymal hemorrhage (hypertensive arteriolosclerosis, amyloid angiopathy) or Subarachnoid Hemorrhage (SAH) (ruptured saccular aneurysm causing “thunderclap” headache). Symptoms stem from direct tissue destruction and elevated intracranial pressure (ICP). |
| Cervical Artery Dissection | Intimal tear in the internal carotid or vertebral artery leading to intramural hematoma, luminal stenosis, or artery-to-artery embolism. A leading cause of stroke in younger adults (<50 years); presents with neck pain, headache, Horner syndrome, and focal deficits. |
2. Clinical Presentation & Symptom Semiology
Clinical manifestations mirror the anatomical distribution of the affected vessel (anterior vs. posterior circulation). Rapid screening utilizing standardized criteria facilitates prompt emergency dispatch and triage.
BE-FAST Emergency Screening Protocol
- B – Balance: Sudden loss of balance, ataxia, or gait instability.
- E – Eyes: Sudden monocular/binocular vision loss, field cuts, or diplopia.
- F – Face: Facial asymmetry or unilateral facial droop.
- A – Arms: Unilateral motor weakness, numbness, or arm drift.
- S – Speech: Slurred speech (dysarthria) or language comprehension/expression deficits (aphasia).
- T – Time: Note “Last Known Well” (LKW) time and activate emergency medical services immediately.
| Clinical Manifestation | Pathophysiologic Basis | Key Clinical Features |
|---|---|---|
| Aphasia | Cortical language network disruption (dominant hemisphere, typically left MCA territory). | Expressive (Broca): Non-fluent, effortful speech with preserved comprehension. Receptive (Wernicke): Fluent, paraphasic speech with impaired comprehension. |
| Dysarthria | Motor articulation deficit secondary to corticobulbar, brainstem, or cerebellar pathways. | Language production, naming, reading, and writing remain fully intact, but speech sounds slurred or garbled. |
| Posterior Circulation Deficits | Vertebrobasilar territory hypoperfusion (brainstem, cerebellum, occipital cortex). | Crossed sensory/motor signs, vertigo, ataxia, dysarthria, diplopia, dysphagia, nausea, vomiting, or bilateral visual field deficits. Often misdiagnosed as peripheral vestibular disease. |
3. Diagnostic Evaluation & Differential Mimics
Determining the exact time of Last Known Well (LKW) is the critical baseline for all hyperacute therapeutic decisions. Diagnostic imaging must rapidly exclude intracranial hemorrhage and identify large vessel occlusions (LVO).
- Point-of-Care Blood Glucose: Must be performed immediately in all suspected stroke cases to rule out severe hypoglycemia, a primary mimic that produces focal neurological deficits.
- Noncontrast Head CT (NCCT): Rapidly excludes hyperdense intracranial hemorrhage, mass lesions, or large established infarcts. Essential prior to thrombolytic administration.
- CT Angiography (CTA) / Perfusion (CTP): Identifies surgically accessible Large Vessel Occlusions (e.g., ICA, M1 segment MCA) and quantifies viable penumbral tissue to determine mechanical thrombectomy eligibility.
- Brain MRI (DWI / ADC): Gold standard for detecting hyperacute cytotoxic edema and small lacunar/posterior circulation ischemic lesions; definitively distinguishes TIA from infarct.
| Common Stroke Mimic | Distinguishing Clinical Features vs. Acute Ischemic Stroke |
|---|---|
| Hypoglycemia | Reversible focal weakness or altered sensorium; rapidly corrects with parenteral dextrose administration. |
| Seizure with Todd Paralysis | Focal postictal motor weakness following an observed or unobserved epileptic event; resolves over hours to days. |
| Migraine with Aura | Characterized by “positive” visual or sensory march (scintillating scotoma, spreading paresthesias) over 5–20 minutes, followed by characteristic headache. (Stroke causes “negative” loss of function). |
4. Hyperacute Intervention Protocols
| Intervention | Therapeutic Window & Criteria | Key Absolute Contraindications & Precautions |
|---|---|---|
| Intravenous Thrombolysis (Alteplase / Tenecteplase) |
Administered within 0 to 4.5 hours of LKW in eligible acute ischemic stroke cases to lyse occlusive thrombi. | Absolute contraindications: Active intracranial hemorrhage, recent severe head trauma/stroke within 3 months, internal bleeding, uncontrolled BP (>185/110 mmHg), severe coagulopathy, or intracranial neoplasm/vascular malformation. |
| Mechanical Thrombectomy (Endovascular Therapy) |
Indicated for confirmed Large Vessel Occlusion (LVO) in the anterior circulation within 0 to 6 hours (extended up to 24 hours in selected patients using advanced perfusion imaging). | Can be combined with IV thrombolysis when eligible. Preserved functional status prior to stroke is a key selection parameter. |
| Hemorrhagic Stroke Management | Immediate acute intervention focused on hemostasis, ICP control, and BP lowering. | Thrombolytics and antiplatelets strictly contraindicated. Require rapid reversal of anticoagulation (e.g., idarucizumab, andexanet alfa, PCC), blood pressure management (target SBP ~140 mmHg), and emergency neurosurgical consultation. |
5. Secondary Prevention & Etiologic Subtyping
Long-term secondary prevention depends directly on establishing stroke pathogenesis using TOAST classification criteria (Large Artery Atherosclerosis, Cardioembolic, Small Vessel Occlusion, Cryptogenic, or Other Specified Etiology).
| Etiology / Mechanism | Evidence-Based Secondary Prevention Strategy |
|---|---|
| Non-Cardioembolic (Atherosclerotic / Small Vessel) |
• Antiplatelet Therapy: Aspirin, Clopidogrel, or Aspirin + extended-release Dipyridamole. • Dual Antiplatelet Therapy (DAPT): Aspirin + Clopidogrel for 21 to 90 days in high-risk TIA (ABCD2 score ≥4) or minor stroke, followed by monotherapy. • Carotid Revascularization: CEA or CAS for symptomatic high-grade (>70%) carotid artery stenosis. |
| Cardioembolic (Atrial Fibrillation / Thrombus) |
• Oral Anticoagulation: DOACs (Apixaban, Rivaroxaban, Dabigatran, Edoxaban) preferred over Warfarin (target INR 2.0–3.0 for mechanical prosthetic heart valves). • Anticoagulation initiation timing depends on post-stroke infarct size and hemorrhagic transformation risk. |
| Vascular Risk Factors (All Subtypes) |
• Blood Pressure Control: Target <130/80 mmHg long-term. • Lipid Management: High-intensity statin therapy (Atorvastatin 80 mg) targeting LDL-C <70 mg/dL (<1.8 mmol/L). • Glycemic Control & Lifestyle: Target HbA1c <7.0%, smoking cessation, weight management, and obstructive sleep apnea screening. |
Clinical Practice Pearls
- Avoid Acute Over-Correction of Blood Pressure: In acute ischemic stroke, moderate hypertension is often permissive to preserve penumbral perfusion. Do not acutely lower BP unless SBP >220 mmHg (or >185/110 mmHg if candidate for IV thrombolysis).
- Stroke Mimic Rapid Rule-Out: Never transport a patient with suspected acute stroke to neuroimaging before verifying capillary blood glucose.
- Fluctuating Symptoms in TIA: A high ABCD2 score after TIA indicates high early stroke risk; urgent inpatient admission and rapid vascular/cardiac workup are mandatory.
